Jump to content
Sclero Forums
janey

Asymmetrical dimethylarginine (ADAM) in systemic sclerosis-related pulmonary arterial hypertension (PAH)

Recommended Posts

Asymmetrical dimethylarginine (ADAM) in systemic sclerosis-related pulmonary arterial hypertension (PAH).

 

In patients with SScPAH, increased ADMA serum levels and their negative association with exercise capacity suggests that the nitric oxide pathway is involved in the development of pulmonary vascular disease. T. Dimitroulas. Rheumatology 2008 47(11):1682-1685. (Also see: Pulmonary Hypertension)

 

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.


Janey Willis

ISN Support Specialist

(Retired) ISN Assistant Webmaster

(Retired) ISN News Director

(Retired) ISN Technical Writer for Training Manuals

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×